multi-organ failure (1) (2) (3) (4) . Results of several studies have demonstrated a lower 1-year patient survival in ALF LT recipients compared to those with cirrhosis undergoing LT because of the emergency nature of the surgery, cerebral oedema, and frequent need for life support in the ALF patients (2, 3) . In addition, a higher rate of allograft dysfunction including acute and chronic rejection, de novo autoimmune hepatitis, and recurrent graft failure have been demonstrated during follow-up in ALF LT recipients (5) (6) (7) . Furthermore, variable degrees of neurological sequelae in long-term survivors of ALF have been reported but the number of patients evaluated has been small (8, 9) .
The USA Acute Liver Failure Study Group (AL-FSG) is a consortium of 13 academic medical centres that is conducting an ongoing observational registry study of adult ALF patients (2) . Important insights into the aetiology, disease-specific prognosis and clinical correlates of early adverse outcomes have been reported (1, 2) . In addition to collecting detailed clinical, demographical, and outcome data up to 3 weeks after enrolment, this study includes a prospective assessment of patient outcomes at 1 and 2 years after enrolment. This effort has proven useful in better defining the long-term clinical outcomes in specific subgroups of ALF patients (10, 11) . The aim of this study was to provide an overview on the 2-year clinical outcomes among initial survivors and LT recipients who were alive 3 weeks after enrolment in the ALFSG. Baseline demographics and clinical factors associated with impaired long-term survival were identified as well as the frequency of various clinical complications among the following three groups: acetaminophen (APAP) initial spontaneous survivors (SS), non-APAP initial SS, and LT recipients. We hypothesized that LT recipients would have poorer long-term outcomes because of their more severe illness necessitating emergency surgery. Multivariate models to identify patients at risk of dying within 2 years of follow-up were constructed to provide prognostic data for clinicians.
Patients and methods

Patient selection
The ALFSG database consists of 1850 adult patients with ALF admitted to one of 13 actively or 10 previously enrolling clinical sites from 1 January 1998 to 1 July 2010. Eligible ALF patients had symptoms of jaundice or illness of <26 weeks prior to admission and mental status changes with coagulopathy defined as an international normalized ratio (INR) >1.5 without known underlying chronic liver disease. The protocol was reviewed and approved by the Institutional Review Board at all of the participating sites and written informed consent was obtained from the patient's next of kin. In addition to baseline demographics and presenting features, detailed information during the first 7 days of enrolment including imaging, lab, and clinical data, as well as short-term outcome data were obtained through 21 days after admission.
Long-term follow-up protocol and data collection
In calendar year 2000, the ALFSG observational study was amended to include a 12-month study visit to be performed at 6-18 months after enrolment as well as a 24-month study visit completed any time after 18 months from enrolment. Data obtained at these visits included incremental medical history, medications, liver biopsy and imaging data, and laboratory variables. In addition, various complications were prospectively tracked including neurological complications. Data were collected at a face to face study visit or via telephone interview and/or chart review. For patients that were lost to follow-up, sites queried the Social Security death index database and reviewed medical records. To be included in the analysis population, patients must have survived to short-term follow-up at 21 days (1138 patients) and either have a recorded death or at least one long-term follow-up form completed 21 days after enrolment (773 patients). For the current analysis, patients were stratified on whether they received a liver transplant (LT), and the 3-week initial spontaneous survivors were further stratified by presence of APAPrelated or other non-APAP aetiology.
Statistical analysis
SAS software version 9.2 (SAS Institute Inc. Cary, NC, USA) was used to perform statistical analysis. Baseline variables were described using counts and percentages for categorical data, or mean and standard deviations (medians and interquartile ranges) for continuous normal (skewed) data. For variables identified as clinically relevant, statistical tests were performed using chisquare, ANOVA, or Kruskal-Wallis tests. Owing to the low event rate in each of the populations, 2-year mortality was reported using cumulative per cent and tested using a test of independent proportions. Predictors of death were modelled with univariate and multivariate logistic regression, with predictors identified using stepwise elimination based on significance and overall goodness of fit. Variables with a P < 0.20 on univariate analyses were considered for the multivariable analysis. Results of the modelling are expressed as odds ratios with 95% confidence intervals. The c-statistic and corresponding 95% confidence interval are based on an approximation (12) . January 1998 and July 2010 (Fig. 1) . Long-term followup data were available in 773 (68%) of these patients. Among the 773 patients included in this analysis, there were 262 LT recipients and 511 initial spontaneous survivors (SS) which included 306 with APAP overdose and 200 with ALF because of other non-APAP aetiologies (Table 1) . The patients not included in this analysis were similar in baseline demographical and clinical features except that the excluded population was more likely to have experienced APAP overdose (Table S1 ).
The 306 patients in the APAP initial SS group were younger and significantly more likely to be female, Caucasian, and of non-Hispanic ethnicity compared to the other two patient groups. As expected, the APAP initial survivors had the shortest duration of symptoms, the highest serum aminotransferase levels and lowest bilirubin levels at presentation. The APAP initial survivors were also significantly more likely to have active psychiatric and substance abuse comorbidities at enrolment and a positive urine toxicology screen. A careful review of the cases demonstrated that 116 of these were intentional APAP overdose patients and 159 were non-intentional therapeutic misadventures, while 31 were of unknown intent. The majority of LT recipients were also women and they had a significantly longer duration of symptoms to jaundice, higher total bilirubin and lower serum aminotransferase levels at presentation compared to the other two groups. The frequency of observed aetiologies of ALF in the LT recipients differed when compared to non-APAP initial SS (P ≤ 0.001). The LT recipients also had the highest INR, lactate, and model for end-stage liver disease (MELD) scores at presentation. Although the level of hepatic encephalopathy was similar in all three patient groups at admission, the LT recipients were more likely to have an intracranial pressure (ICP) monitor placed, require mechanical intubation, and receive pressors and mannitol during their illness compared to the other two patient groups.
Two-year patient survival
The 2-year actuarial patient survival was highest in the LT recipients (92.4%) followed by the APAP initial SS (89.5%) and non-APAP initial SS (75.5%). Cumulative death rates are presented in Fig. 2 . The median time to death in the LT recipients of 223 days (range: 23-568 days) was significantly longer compared to the other two patient groups (P < 0.001). Overall, the leading causes of death were liver related (17%), infection/ sepsis (12%), and multisystem organ failure (18%), but 45% of the deaths were of unknown cause ( Table 2 ). The identified causes of death were similar in the three patients groups.
Predictors of impaired long-term survival
Multivariate models were constructed to identify baseline variables associated with impaired 2-year survival in each of the three patient groups (Table 3 ). Univariate analyses of the admission clinical data were used to identify potential variables for model building.
Acetaminophen initial spontaneous survivors
Older patient age, serum alanine aminotransferase (ALT) as well as elevated serum phosphate, lower arterial pH, and higher initial coma grade were significant predictors of death on univariate analysis. In the multivariate model, age and phosphate remained as consistent predictors of death with an elevated phosphate level indicating higher risk of death (OR: 1.26, 95% CI: 1.05, 1.51). The median age of the APAP patients that died during follow-up was 42, while the median age of the long-term survivors was 35. The median admission phosphate of those that died was 2.75 mg/dl compared to 2.20 mg/dl in those that survived. Of note, the proportion of patients with intentional APAP overdose was similar in the long-term survivors and non-survivors (41% vs. 42%, P = 0.93) as was the presence of psychiatric comorbidities (44% vs. 56%, P = 0.19).
Non-acetaminophen spontaneous survivor group
Older patient age, non-Hispanic ethnicity, <12 years of education, increased days of jaundice to ALF, serum ALT, higher INR and pressor use were examined as potential predictors of death for the multivariate analysis. Of note, initial coma grade, need for dialysis and intubation were not associated with long-term survival in univariate analyses. In the multivariate model, age and days from jaundice to ALF were the only independent predictors of death in this patient group. The median age of the non-APAP patients who died was 50 vs. 42 in those that survived. The aetiologies of ALF in Fig. 1 . ALF patients included in the current analysis. Among the 773 ALF patients eligible for this study, there were 262 liver transplant (LT) recipients and 511 initial spontaneous survivors (SS) who were alive 3 weeks after enrolment into the ALFSG registry. those who died varied, but there was no specific non-APAP aetiology which was over-represented in those who died vs. survived (Table S2a , P = 0.35). Of the 49 patients who died with non-APAP ALF, only five (10.2%) were listed for liver transplant, while 32 of the 151 survivors (21.1%) were initially listed for LT during their hospitalization.
Liver transplant recipients
In the multivariate model for LT recipients, age, days from jaundice to ALF onset and higher coma grade remained as consistent predictors of death with older patient age indicating higher risk of death (10 years OR: 1.53, 95% CI: 1.06, 2.21). There did not appear to be an over-representation of any particular aetiology of ALF in those who died vs. survived (Table S2b , P = 0.07). However, 12% of the APAP LT recipients died as well as 11% of the autoimmune patients and 5% of the druginduced liver injury (DILI) patients. Although the proportion of patients with advanced encephalopathy (Grade ¾) at presentation was significant on univariate analysis, this did not persist in multivariate analysis. The median age of the LT recipients who died was 45.5 compared to 38 years in those who survived. The median days to jaundice of the LT recipients who died was 6 compared to 12 in those who survived. The proportion of LT recipients who died that had grade ¾ HE was 60% compared to 36% in those who survived.
Long-term clinical and functional outcomes
Assessment of long-term functional outcomes are reported in Table 4 from the 353 patients who provided follow-up data in person or via telephone interview including 123 APAP initial survivors, 85 non-APAP initial survivors and 145 LT recipients. The rate of employment, marriage and having private insurance was lowest in the APAP patients compared to others. In the subgroup of patients with an available Karnofsky score, the median score among the APAP initial survivors was lower than the other two groups but this difference was not statistically significant.
Medical and psychiatric comorbidities during long-term follow-up
The frequency of diabetes, hypertension and hyperlipidaemia in the three groups were similar at the last available long-term follow-up study visit (Table 4) . However, ongoing psychiatric illness was significantly more common in the APAP SS patients compared to the other groups. Furthermore, problematic alcohol consumption was significantly more commonly reported in the APAP group compared to the others and intentional drug overdose/suicide was also significantly more common in the APAP SS patients.
Liver disease and laboratory status
The median values of serum AST, ALT, alk phos and bilirubin were normal at the last available follow-up visit in the three subgroups of patients. However, the median serum total bilirubin levels were significantly lower in the LT recipients compared to the other patient groups while the median serum creatinine levels were significantly higher in the LT recipients (Table 4) .
Discussion
ALF is a rare but potentially devastating illness that frequently afflicts previously healthy and young individuals. The ALFSG and other groups have previously reported that 3-week transplant-free survival is significantly higher in subjects with APAP overdose, hepatitis A, and pregnancy-related ALF (~60 to 70%) compared to subjects with DILI, Wilson's disease and indeterminate ALF (~20 to 40%) (1-4). In addition, the ALFSG demonstrated that patient age, initial and peak grade of hepatic encephalopathy, and selected laboratory variables are associated with a greater likelihood of death during the initial ALF hospitalization (1, 2). Currently, many clinicians use these parameters and other laboratory and clinical features at the bedside to help guide decisions regarding the need to list and proceed with LT (3, 4) . However, the long-term clinical outcomes in ALF patients who survive their initial illness are not well described. Understanding long-term outcomes in initial survivors with ALF has proven difficult because of the low incidence of the disease in the general population with only 2000-3000 annual cases in the USA.
In this study, we were able to determine the 2-year clinical outcomes in 773 ALF patients who had survived their initial illness. The patients included in this analysis are generally representative of the entire ALFSG cohort, although fewer APAP patients were included compared to the overall cohort (Table S1 ). Liver transplantation yielded the highest 2-year survival at 92.4% compared to the other two groups of initial spontaneous survivors. These results are somewhat surprising as subjects who require an emergency LT tend to be sicker at presentation compared to subjects that spontaneously recover and would be expected to continue to have a substantial risk of death during prolonged follow-up. The greater initial severity of illness at presentation among the LT recipients is supported by the higher initial and peak serum bilirubin, INR, lactate and MELD scores in these patients compared to the other two groups ( Table 1) . The 20 deaths in the LT recipients occurred throughout the 2 years of follow-up, while most of the deaths in the initial spontaneous survivors tended to occur within 6 months of enrolment into the ALFSG study, suggesting that ongoing hepatic damage may lead to fatal outcomes after the initial illness. In attempting to understand the reasons for the absolute differences in mortality and time to death, we first looked at the causes of death in the three patient groups. There was no apparent differences in the stated causes of death but there were moderate number of 'unknown' causes in each subgroup (Table 2) . A recent study of hospitalized adult patients with APAP overdose in Canada demonstrated that many of the patients died during 5 years of follow-up from a variety of preventable causes including trauma, substance abuse and other high-risk behaviours (13) . In addition, the survival of the APAP overdose patients was significantly lower than the expected rate in age-matched population controls. Therefore, the observation that roughly 10% of our APAP initial survivors died during 2 years of follow-up is not entirely surprising. Our data also suggest that the increased frequency of medical and psychiatric comorbidities in these highrisk patients may require additional treatments and interventions to improve long-term outcomes.
To further explore the observed differences in mortality, models of 2-year patient mortality were constructed using baseline variables in all three patient subgroups (Table 3) . Of note, a higher patient age at admission was significantly associated with impaired survival in both the LT and non-APAP initial survivor groups. These data are consistent with results of prior studies of LT recipients which have also demonstrated that increased patient age is a strong negative predictor of survival in ALF patients (14) (15) (16) . Other studies have also demonstrated that liver regeneration is impaired in older livers (14, 17) . Therefore, our data are consistent with prior studies demonstrating the importance of subject age in surviving severe acute liver injury. In each of the subgroups, specific baseline features were identified as being associated with impaired survival on multivariate analysis (Table 3) . Among the APAP patients, a higher phosphate level was associated with poorer survival which is consistent with prior studies demonstrating that hyperphosphataemia is associated with poorer short-term outcomes (18, 19) . This association may be because of impaired utilization of phosphate in liver regeneration or simply as a marker of patients with poorer renal function. Unfortunately, serial serum phosphate levels during the ALF hospitalization or during long-term follow-up were not available for testing. In addition, a lower arterial pH and higher arterial lactate levels are important predictors of short-term outcomes in the King's college criteria and arterial pH and INR were significant but only on univariate analysis in our cohort (3, 4) . However, we did not detect a poorer long-term survival in APAP patients with more advanced encephalopathy at presentation. Nonetheless, other studies have demonstrated that severe cerebral oedema is predictive of poor neurological outcomes and survival in ALF patients (20, 21) .
Among the non-APAP initial survivors, age, serum ALT levels, and a longer duration of symptoms were all identified on univariate analyses as associated with a lower likelihood of long-term survival (3, (21) (22) (23) (24) . The ALFSG has previously shown that Hispanic patients are more likely to have a lower transplant-free survival rate compared to non-Hispanic patients in part because of their greater likelihood of having DILI (25) . However in multivariate analysis, only patient age and a longer duration of symptoms to ALF onset were significant and independent predictors of death. A poorer outcome in patients with subacute ALF that present with more slowly but inevitably progressive liver injury than those with hyperacute ALF has been previously reported (26, 27) . Furthermore, the majority of these non-APAP patients were never listed for LT and nearly 20% had ALF because of ischaemic hepatitis which is associated with severe underlying cardiopulmonary disease that frequently precludes LT (10) .
Among the LT recipients, patient age and more advanced encephalopathy at presentation were associated with poorer 2-year survival on univariate analyses. These data are consistent with prior studies that demonstrate the critical importance of the initial and peak encephalopathy grade in predicting outcome in ALF (3, 28, 29) . However, in multivariate analysis only age and the days from jaundice to ALF onset remained independent predictors of outcomes. Although other studies have demonstrated that LT recipients with APAP overdose are at increased risk of graft failure compared to Liver International (2015) other ALF patients, we were not able to identify a relationship between the aetiology of ALF and death during prolonged follow-up possibly because of the limited number of deaths in this population.
A careful review of the functional outcomes in the three patient groups demonstrated some important and interesting differences (Table 4) . For example, LT recipients were significantly more likely to be employed compared to the other two groups both at presentation and during follow-up. These observations may in part be because of the lower socioeconomic status of patients who present with APAP overdose compared to the other two groups. Although nearly 40% of the APAP overdose patients were non-intentional 'therapeutic misadventures' who received toxic doses of multiple APAP products there was a significantly higher rate of concomitant substance abuse and psychiatric disease requiring treatment in the APAP SS group during follow-up compared to the other two groups which was independent of intentionality (29) . In addition, 6.1% of the APAP initial survivors reported another episode of drug overdose/suicide which is also consistent with prior studies of repeated high-risk behaviours in this patient population (13) .
Recent studies have demonstrated that LT recipients with ALF have a lower rate of employment compared to cirrhotic LT recipients despite their younger age (30) . In addition, ALF patients experience higher rates of depression, anxiety, and post-traumatic stress disorder after liver transplantation compared to cirrhotic LT recipients (31) . Whether this is because of the sudden onset of a severe life-threatening illness in generally young and previously well ALF patients compared to chronically ill cirrhotic LT recipients is not known but plausible. The Karnofsky scores which are indicative of global health status tended to be higher in the LT recipients compared to the other two groups although the difference did not reach statistical significance. In a recent analysis of health related quality of life measures in a subgroup of ALFSG long-term survivors, we showed that the LT recipients had significantly higher SF-36 and CDC-14 scores during follow-up compared to the APAP and non-APAP initial survivors (32) . These cumulative data suggest that both APAP and non-APAP initial survivors appear to have poorer general physical and mental health compared to the LT recipients during longterm follow-up in addition to a lower overall survival. As such, a significant subset of ALF spontaneous survivors may benefit from targeted interventions including counselling, psychiatric care, and physical therapy to achieve improved long-term health outcomes.
The median serum AST, ALT, alk phos, and bilirubin levels were normal in all of the patients in each of the three patient subgroups during their most recent follow-up visit (Table 4 ). The significantly lower total bilirubin levels in the LT recipients is somewhat surprising and suggests that the APAP and non-APAP initial survivors may have poorer bilirubin clearance. However, our study was not designed to assess liver disease status via histological sampling or radiological imaging to further explore this observation. We surmise that the higher mean serum creatinine levels in the LT recipients likely relates to the use of nephrotoxic calcineurin inhibitors to prevent rejection. However, only 28% of the LT recipients had an elevated serum creatinine level so the degree of renal insufficiency appears to be mild. In addition, the incidence of diabetes and hypertension was generally low and similar in the three patient groups.
Limitations of this study include the incomplete follow-up of all 1172 eligible ALF survivors at 3 weeks (Fig. 1) . One of the reasons for incomplete follow-up is that over 80% of the ALF patients are transferred to an ALFSG site for tertiary liver care. For patients that survive their index hospitalization with no evidence of residual liver injury, continued follow-up at a referral centre that may be several hours from their home, can be challenging. This may in part explain the larger proportion of APAP initial survivors who did not return for follow-up (Table S1 ). In addition, continued participation in a non-interventional registry study would be expected to have a lower rate of follow-up than a clinical trial. Lastly, 45% of the ALF patients that died during prolonged follow-up did not have an identifiable cause of death (Table 2 ). This rate of incomplete data is similar to those seen in other population and cohort-based studies of long-term outcomes of patients (33, 34) . The incomplete reporting of the causes of death in our study may again relate to the absence of long-term medical follow-up in the liver centre because of logistical issues as well as our inability to routinely obtain Death Certificates or causes of death from the Social Security Death Index. In addition, the declining use of autopsy in patients that die in a hospital setting and the difficulty to accurately ascertain the cause of death in individuals without an autopsy may have played a role (33, 35, 36) . Despite these limitations, our study represents the largest cohort of adult ALF patients that were prospectively followed beyond 21 days and up to 2 years. In addition, the severity of illness and other clinical features of the enrolled patients were generally similar to the excluded patients. Another limitation of this study was that we did not account for donor, operative or immunosuppression variables when attempting to explore outcomes in the LT recipients. This was because of the fact that our study was not intended to standardize the treatment or monitoring of ALF patients after LT. Furthermore, the limited number of deaths in the LT recipients may have precluded adequate power to identify other predictors of long-term outcomes.
In conclusion, our study results demonstrate that the 2-year clinical outcomes in early survivors with ALF are generally very good. Although nearly 40% of initial adult ALF patients die during their index hospitalization, the mortality rate among initial 3-week survivors is substantially lower during more prolonged follow-up. Contrary to our initial hypothesis, the non-APAP initial survivors have a significantly lower 2-year survival compared to the LT recipients and APAP initial survivors. Most of the deaths in the initial spontaneous survivors occurred within the first 6 months of observation because of a multitude of causes suggesting that early careful follow-up after an ALF episode is warranted. Among the long-term survivors, the APAP initial survivors had the lowest rates of employment which may be because of their lower baseline socioeconomic status and more frequent medical and psychiatric comorbidities compared to the other patient groups. Laboratory markers of liver injury demonstrated normal or near normal parameters in most patients during follow-up. Therefore, despite the need for intubation, dialysis and pressors in many ALF patients during their acute illness, most will recover with intact liver function during follow-up. Although mortality is highest in the non-APAP initial survivors, the overall favourable 2-year survival can help guide future studies of additional interventions to improve clinical outcomes in these patients.
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